These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2015-005594-21 A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma 2019-06-18 due-trials
Ongoing 2018-004888-31 Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor Follow-up a lungo termine dei partecipanti esposti a GSK337779... not-yet-due
Other 2019-000589-39 A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma not-yet-due
Reported results 2020-005802-24 A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers Ensayo clínico en fase II y sin enmascaramiento de ADP-A2M4CD8 en pacient... 2023-06-09 due-trials
Other 2022-003176-16 A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084) not-yet-due